Trial Profile
An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms APEC
- Sponsors Merck KGaA
- 03 Jul 2021 Results of subgroup analyses from EREBUS, ERBITAG and CEBIFOX assessing overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer APEC presented at the 23rd World Congress on Gastrointestinal Cancer
- 05 Jun 2018 Results (n=167) of subgroup analysis assessing the impact of tumor side in the APEC study population with RAS wt mCRC presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 20 Jan 2018 Results of subgroup analysis assessing impact of tumor side, presented at the 2018 Gastrointestinal Cancers Symposium.